Tenotryl™ (enrofloxacin) injectable solution (Cattle)

One shot, two active molecules

Enrofloxacin, the active ingredient in Tenotryl™ is an efficient, broad-spectrum antibiotic that has been trusted in the U.S. cattle industry for 25 years. Once injected, enrofloxacin is metabolized into enrofloxacin and ciprofloxacin.¹ These molecules deliver different modes of action for optimal efficacy. Therefore this product delivers prompt, combined strengths against the primary pathogens that cause bovine respiratory disease (BRD).

 

Proven in the Field

• First treatment of BRD in a feedlot

 

Please check out more on Tenotryl™ (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution Trial on AABP Podcast link below.

 

Dosing options to meet the need of your operation

Tenotryl is labeled for cattle and swine. The information provided on this page is provided specifically for cattle. See the Tenotryl swine webpage for more information.

Indications:

Single-Dose Therapy: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.

Multiple-Day Therapy: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle.

 

CATTLE IMPORTANT SAFETY INFORMATION

Tenotryl™ (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution:  Not for use in humans.  For subcutaneous use in beef cattle and non-lactating dairy cattle.  Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian and prohibits the extra-label use of this drug in food producing animals. Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows.  Use in these cattle may cause drug residues in milk and/or in the calves born to these cows.  A withdrawal period has not been established for this product in pre-ruminating calves.  The effects of enrofloxicin on cattle reproductive performance, pregnancy and lactation have not been adequately determined.  Do not exceed a 20 mL dose per injection site.  Subcutaneous injection in cattle can cause a transient local tissue reaction and may result in trim loss of edible tissue at slaughter.  Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. Download the product insert here.

 

References

1. McKellar, Q., Gibson, I., Monteiro, A., Bregante, M. 1999. Pharmacokinetics of Enrofloxacin and Danofloxacin in Plasma, Inflammatory Exudate, and Bronchial Secretions of Calves following Subcutaneous Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1999, p. 1988–1992.